Functional Analysis of Complex Structural and Splice‐Altering Variants in the ARSB Gene Towards the Personalized Antisense‐Based Therapy for Mucopolysaccharidosis Type VI Patients

• Published in: Human mutation 2025-01, Vol.2025 (1)
• Main Authors: Bychkov, Igor, Filatova, Alexandra, Baydakova, Galina, Sikora, Nataliya, Garifullina, Emiliya, Bykova, Anna, Tabakov, Vyacheslav, Skretnev, Alexandr, Skoblov, Mikhail, Zakharova, Ekaterina
• Format: Article
• Language: English
• Subjects: Antisense therapy; Enzymes; Genes; Hypotheses; Maroteaux-Lamy syndrome; Mucopolysaccharidosis; Patients; Polymerase chain reaction; Structure-function relationships
• ISSN: 1059-7794; 1098-1004
• DOI: 10.1155/humu/2250030

Mucopolysaccharidosis Type VI (MPS VI) is a lysosomal storage disorder associated with biallelic pathogenic variants in the ARSB gene. Herein, we present three patients with biochemical and clinical pictures of MPS VI, for whom routine molecular genetic analysis using Sanger sequencing of ARSB failed to identify one or both causative variants. RNA analysis of patients’ samples revealed alterations of the wild‐type ARSB mRNA isoform in all cases, and one case required further analysis using whole genome sequencing. As a result, we identified one complex structural variant, which is a 52‐kb insertion of the LHFPL2 gene fragment in the ARSB Intron 4, derived from nonallelic homologous recombination and leading to premature transcription termination, a recurrent deep intronic variant leading to pseudoexon activation and an intragenic deletion altering the integrity and splicing of the ARSB Exon 2. Using a minigene‐based cellular model, we demonstrated that the identified pseudoexon can be efficiently blocked by antisense molecules incorporated into modified U7 small nuclear RNAs and circular RNAs. The same approach was used to block the overlapping polymorphic pseudoexon in the ARSB gene and increase the amount of wild‐type mRNA isoform approximately twofold.